In a recent update to its global cannabis market forecast, BDSA, headquartered in Colorado, has revised its sales projections. The new estimate anticipates that the industry will reach $55 billion in sales by 2027, representing substantial growth from the $32 billion recorded in 2022.

However, this forecast represents a notable decrease compared to BDSA’s earlier projection earlier in the year, which had predicted global marijuana sales to approach $60 billion by 2027. BDSA executives attributed this adjustment to Germany’s decision to deviate from its initial plan for a comprehensive recreational market, instead opting for a more restricted pilot program.

BDSA clarified this shift, stating, “The primary factor in the reduction of BDSA’s forecast for 2027 was the removal of the assumption for a full commercial adult launch in Germany, which had been assumed to begin in 2024 and forecast to reach nearly $3.6 billion in 2023.”

Furthermore, BDSA’s updated forecast also incorporates lower-than-anticipated U.S. cannabis sales in the coming four years, now projected to reach $43 billion by 2027, down from the previous estimate of approximately $45 billion. This adjustment is attributed to a reassessment of various constituent markets and channels, based on 2023 sales data, as well as “slower adult-use growth expectations in more mature markets, with some contribution from weakness in formerly robust medical markets.”

When questioned about the specific challenges faced in California, BDSA pointed to “high taxes, operational costs, and other issues” as factors creating a challenging environment for legal cannabis businesses. Consequently, some businesses have exited the California market over the past year.

One encouraging aspect highlighted by BDSA is the diminishing illicit cannabis spending and the concurrent growth of legal spending in almost all modeled markets. This has been a persistent challenge for California and several other U.S. cannabis markets.

According to the report, the U.S. is still expected to dominate the state-sanctioned marijuana sales market, with the rest of the world projected to contribute just $11.6 billion in 2027, constituting about one-fifth of the total legal cannabis commerce.

BDSA predicts that the primary driver of growth in U.S. marijuana sales over the next four years will be emerging markets, particularly on the East Coast and in the Midwest. Specific markets such as New York, New Jersey, Maryland, Michigan, and Missouri are identified as having substantial growth potential. CEO Roy Bingham of BDSA highlighted the expected $2.5 billion markets for both New York and New Jersey and described Michigan as an “outlier” likely to achieve $3.8 billion in sales by 2027.

However, the forecast also indicates challenges for mature markets like California and Colorado, with stagnating or declining sales. BDSA anticipates modest growth in California by 2025, with sales projected to surpass $5.2 billion in 2027. In Colorado, sales are stabilizing, expected to reach $1.6 billion this year following a decline in 2022, and then experiencing minimal growth to $1.7 billion by 2027.

North of the border, Canada’s legal cannabis sales are forecasted to rise by 9% this year, reaching $4.6 billion, with the potential to reach $5.3 billion within four years.

Regarding the rest of the world, BDSA’s projections suggest that international sales, excluding Canada, will amount to about $2.4 billion in 2023, surging to $6.3 billion by 2027. Notable international markets apart from Canada include Mexico, expected to achieve $1.5 billion in sales by 2027, and Germany, which is in the process of implementing an adult-use cannabis pilot program.

Source: Green Market Report


Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Revolutionary Shift: US Health Department Proposes Reclassifying Marijuana from Schedule I to Schedule III

In a groundbreaking move that has the potential to reshape the landscape of cannabis regulations, the U.S. Department of Health and Human Services (HHS) has taken a bold step by formally recommending the reclassification of marijuana from Schedule I to Schedule III under federal law. This historic decision signifies a seismic shift in perspective, indicating that the nation’s premier health agency no longer views cannabis as a substance with high abuse potential and zero medical value.

Cultivating Sustainability: Harnessing Solar Power for a Greener Cannabis Industry

In the quest for sustainability, the cannabis industry has emerged as an unlikely candidate for the adoption of solar power solutions. The cannabis cultivation sector, driven primarily by indoor growing facilities, has historically been associated with high energy consumption and significant carbon footprints. However, as the industry matures and faces mounting pressure to reduce its environmental impact, solar power is increasingly being recognized as a game-changer in the pursuit of greener, more sustainable cannabis production.

U.S. Cannabis Sales Could Total $71B in 2030 Without Federal Legalization

The recently released 2023 U.S. Cannabis Report by New Frontier Data has shed light on the remarkable growth potential of the cannabis industry in the United States. With state-level legalization gaining momentum and the absence of federal policy reform, the report predicts a substantial increase in annual cannabis sales over the next seven years.